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The evolutionary process has conferred a dual – enzymatic and signaling – function on
the ancestral metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which has long
been known for converting the essential amino acid tryptophan (TRP) into neuroactive and
immunoactive catabolites (kynurenines). In addition to TRP catabolic activity, phosphory-
lated immunoreceptor tyrosine-based inhibitory motifs, present in the IDO1 protein, act
as docking sites for different molecular partners, which activate positive (transcriptional) or
negative (post-translational) modulation of IDO1 protein. The ligand-operated transcription
factor aryl hydrocarbon receptor (AhR) contributes to Ido1 transcription, and it can be oper-
ated by both exogenous and endogenous ligands, including L-kynurenine itself, the first
byproduct of TRP catabolism. Ligand-bound AhR is also a component of a ubiquitin ligase
complex responsible for regulatory proteolysis of different target proteins. Because IDO1
half-life is controlled by the ubiquitin–proteasome system, we here discuss the possibility
that AhR, in addition to enhancing Ido1 transcription, contributes to IDO1 regulation by a
non-genomic mechanism affecting the protein’s half-life.
Keywords: IDO1, AhR, ITIM, ubiquitin ligase complex, tryptophan metabolism, L-kynurenine, immunoregulation,
dendritic cells
INTRODUCTION
Fine tuning of immune reactivity is guaranteed by the recruitment
of enzymes with disparate and pleiotropic functions. Indoleamine
2,3-dioxygenase 1 (IDO1) was first recognized as an immune regu-
lator in pregnancy (1), and subsequently, in numerous experimen-
tal and clinical settings, including autoimmune diseases, chronic
inflammation, transplantation, and neoplasia (2). IDO1 catalyzes
degradation of the essential amino acid tryptophan (TRP) along
a pathway that causes TRP starvation and yields several biologi-
cally active catabolites, collectively known as kynurenines. Similar
to other metabolic enzymes, IDO1 is endowed with a second
(“moonlighting”) function, which makes it a signal-transducing
molecule owing to the presence of two immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) (3, 4). When phosphorylated,
those motifs act as docking sites for distinct molecular part-
ners, which can either prolong IDO1’s half-life – thus sustaining
immunoregulatory effects – or shorten its half-life, so favoring
inflammatory responses (5).
The aryl hydrocarbon receptor (AhR), a ligand-activated tran-
scription factor that mediates dioxin toxicity (6), is of vital impor-
tance in the regulation of immune responses. Unbound AhR is
sequestered in the cytosol by the Hsp90/XAP2 chaperon complex
(7–10). Ligand binding to AhR induces conformational changes
that promote nuclear translocation of the receptor. In associa-
tion with the AhR nuclear translocator (Arnt), AhR modulates
the transcription of target genes through AhR-responsive ele-
ments (AHREs) (7, 8, 10). A wide array of distinct exogenous
and endogenous ligands bind AhR, including indole-containing
molecules and TRP metabolites such as l-kynurenine (l-kyn), the
upstream metabolite generated via TRP degradation (11, 12). The
immunoregulatory effects mediated by AhR have been known to
mostly involve its genomic activity, contributing to Ido1 transcrip-
tion (13). However, AhR is also involved in a non-genomic path-
way, being a component of an atypical ubiquitin ligase complex,
which regulates the proteasomal degradation of target proteins
(14–16).
REGULATORY PROTEOLYSIS OF IDO1 ENZYME
Intracellular proteins are continually “turning over” as they
become hydrolyzed to their constituent amino acids and replaced
by new synthesis, which absolves to several important homeostatic
functions. Cells contain multiple proteolytic systems to carry out
the degradation process and complex regulatory mechanisms, to
ensure that the continual proteolytic processes are highly selec-
tive. In all tissues, the ubiquitin–proteasome system presides over
the degradation of the majority of intracellular proteins (17).
In dendritic cells (DCs), under inflammatory conditions, IDO1
itself undergoes proteasomal degradation by associating with sup-
pressor of cytokine signaling 3 (SOCS3) through tyrosine phos-
phorylated ITIMs present in an IDO1 domain distinct from that
mediating its enzymatic function (3).
The crystal structure of the enzyme has indeed been solved
in its catalytically inactive conformation (18), unveiling the pres-
ence of two folding domains, namely, a large domain and a small
domain. The former contains the heme-binding site, forming the
catalytic cleft of the enzyme, while the latter contains two highly
conserved ITIMs, which, once tyrosine phosphorylated, can act
as docking sites for the association with different molecule part-
ners (5). Remarkably, the inspection of the crystal structure of the
enzyme (pdb code: 2D0T, 2D0U) shows that the phosphorylable
ITIM tyrosines are unexposed to the solvent, and thus,poorly com-
patible with the experimentally observed interaction with SOCS3.
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Multiple conformational states of enzymes have been reported
to play a role in molecular recognition, catalysis, and allosteric
modulation (19–21). Compliant to this paradigm, conformational
fluctuations of the large and small domains of IDO1 may exist and
be triggered by ligand binding and/or by post-translational mod-
ifications. Hence, the aforementioned tyrosine phosphorylation
of IDO1’s ITIMs may promote a specific conformational state of
IDO1, amenable the interaction with SOCS3.
Suppressor of cytokine signaling 3 represents the first IDO1
partner identified so far, capable of binding the ITIM docking sites
in the enzyme. As a member of the SOCS protein family, it acts as
a feedback inhibitor, blocking JAK/STAT signaling in response to
pro-inflammatory cytokines, such as IL-6. SOCS3 possesses a Src
homology 2 (SH2) domain, binding phosphotyrosine-containing
peptides, and a SOCS box, which recruits an E3 ubiquitin lig-
ase complex and targets several signaling proteins, disparate in
nature, for ubiquitination and proteasomal degradation (22, 23).
We have previously provided evidence that the SH2 domain in
SOCS3, by anchoring phosphorylated IDO1’s ITIMs, brings the
enzyme close to the E3 ubiquitin complex that ubiquitinates and
targets IDO1 for proteasomal degradation. This mechanism pro-
vides an explanation for the observed, inverse relationship between
SOCS3 and IDO1 expression in DCs. In fact, in DCs lacking
SOCS3, the immunoadjuvant effect of the immunogenic fusion
protein CD28-Ig is lost, and the latter behaves much like cyto-
toxic T lymphocyte-associated antigen 4 (CTLA4)-Ig, which is
immune suppressive in nature (24). This has been traced to CD28-
Ig’s unique ability to trigger IL-6 and SOCS3 activities, a property
unshared by CTLA4-Ig. IL-6-induced SOCS3 is indeed responsible
for degrading the protein product of Ido1, whose transcriptional
activation is mediated by IFN-γ (25). Mutations of the phospho-
rylable tyrosines in IDO1’s ITIM domains completely abolish the
ability of the enzyme to bind SOCS3, thus preventing its targeting
for proteasomal degradation (3, 26).
Therefore, the IDO1/SOCS3 association in DCs represents
a molecular mechanism whereby IDO1-positive (IDO1+) DCs,
expressing a tolerogenic phenotype, can turn into immunostimu-
latory antigen presenting cells (APCs), according to environmental
needs (3). According to the variety of pathophysiologic contexts
that DCs must face, proteasomal degradation of IDO1 could rep-
resent a non-genomic mechanism of modulation of the enzyme
in order to promptly turn IDO+ DCs into immunogenic IDO-
negative DCs under conditions in the local microenvironment that
require activation of the immune response. Regulatory proteolysis
of IDO1 by the ubiquitin–proteasome system may be a more com-
mon event than previously appreciated, and it may involve other
pathway besides that of IL-6-induced SOCS3 activation.
LIGAND-DEPENDENT E3 UBIQUITIN LIGASE ACTIVITY OF AhR
Although AhR has traditionally been defined as a transcrip-
tion factor involved in adaptive xenobiotic and in environmental
pollutant responses – including polycyclic and halogenated aro-
matic hydrocarbons, such as 2,3,7,8-tetrachorodibenzo-p-dioxin
(TCDD,“dioxin”) – the direct transcriptional activity of AhR alone
does not fully explain its toxicological and physiological effects.
Accumulating evidence suggests that AhR exhibits its regulatory
functions by “cross-talking” with a variety of signaling pathways,
including estrogen (ER) and androgen (AR) receptors (27, 28). In
addition to its genomic activity, AhR is also capable of mediating
non-genomic effects, by assembling an atypical E3 ubiquitin ligase
complex, CUL4BAhR that includes cullin 4B (CUL4B) (14, 28). E3
ubiquitin ligases act in the last step of a sequential reaction, also
involving E1 and E2 ligases, and culminating in the ubiquitination
of protein substrates.
Similar to the aforementioned ubiquitin ligase activity, medi-
ated by SOCS3 with IDO1 being the target protein, the ubiquitin
ligase activity of CUL4BAhR complex has been reported to target
several types of protein for proteolysis. Besides the transcriptional
regulation of ERs and ARs, ligand-operating AhR has recently
been shown to promote proteasomal degradation of the very
same receptors, by assembling the CUL4BAhR E3 ubiquitin ligase
complex (15). Similarly, ligand-based assembly of the CUL4BAhR
E3 ligase complex has been found to promote ubiquitination
of β-catenin (16), a transcription factor downstream from the
Wnt signaling pathway, leading to proteasomal degradation of β-
catenin in colon tumor cell lines. Interestingly, AhR-deficient mice
frequently develop colon tumor with abnormal accumulation of
β-catenin protein. Inversely, administration of AhR ligands effi-
ciently suppressed colon cancer in an established mouse model of
familial adenomatous polyposis. These findings suggest that AhR
ligands can be used to successfully prevent intestinal tumors, where
increased stabilization and accumulation of β-catenin may be
responsible for the initiation of intestinal carcinogenesis. Notably,
the substrates of CUL4BAhR ubiquitin ligase complex – ER, AR,
and β-catenin – all promote cellular proliferation in their target
tissues, suggesting that one putative biological role of the ubiqui-
tin ligase function of AhR could be the antiproliferative activity
through degradation of those transcription factors, promoting cell
proliferation. This raises the possibility of developing selective AhR
ligands in cancer therapy, by promoting ubiquitin ligase function.
Besides a direct role of AhR in assembling an ubiquitin ligase
complex, there is evidence that AhR may indirectly promote ubiq-
uitination of target proteins. One such recent mechanism has been
described for SOCS2-induced proteasomal degradation of tumor
necrosis factor receptor-associated factor (TRAF)6 in a model of
Toxoplasma gondii infection. In this study, both l-kyn and the
lipoxin LXA4 were found to induce SOCS2-dependent ubiquiti-
nation and proteasomal degradation of TRAF6, hindering pro-
inflammatory cytokine expression by DCs. In this case, the mech-
anism was mediated by the transcriptional activity of AhR, leading
to SOCS2 expression that, in turn, promoted TRAF6 polyubiquiti-
nation and proteasomal degradation of the adapter proteins (29).
Taken together, the results provide compelling evidence of a
prototypic indirect mechanism by which AhR, through AHRE
promoter-carrying genes (which include Socs2 and, interestingly,
Socs3) can mediate the proteasomal degradation of target pro-
teins. Notably, l-kyn is a TRP metabolite generated by IDO1 in
tolerogenic DCs (30), and it acts as endogenous ligand of AhR in
promoting IDO1 phosphorylation, leading to TGF-β production
(13). Moreover, the interaction of l-kyn with AhR can gener-
ate regulatory T cells (12). Overall, these observations shed light
on the crucial relationship between TRP metabolism and both
the genomic and non-genomic activities of AhR in modulating
immune responses.
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PERSPECTIVE ON AhR-MEDIATED, NON-GENOMIC
MODULATION OF IDO1
Several experimental models dissected the tight relationship
between TRP metabolism and the activity of AhR in modulat-
ing the immune response. It is well established that l-kyn, the
upstream metabolite generated by TRP-degrading enzymes, acts
as an endogenous AhR ligand, leading to generation of regulatory
T cells, and participating in immune homeostasis (12, 31). The
IDO1–AhR axis has been described in several settings of immune
tolerance, including maternal–fetal tolerance (32), immune sup-
pression induced by several human cancers (33), and endotoxin
tolerance (13). Therefore, the molecular dissection of the mech-
anisms that sustain the immunoregulatory IDO1–AhR axis has
become a compelling need.
As a transcription factor, AhR promotes IDO1 expression in
response to structurally disparate ligands such as l-kyn – in con-
ventional DCs in a model of endotoxin tolerance (13) – and TCDD,
during maturation of bone marrow-derived DCs (34), making
Ido1 as an AhR-responsive gene. Moreover, an autocrine signal-
ing loop involving IL-6, STAT3, and AhR was found to sustain
the constitutive expression of IDO1 in human cancer cells (33).
The genomic modulation of IDO1 by ligand-operating AhR also
involves non-canonical mechanisms mediated by kinase activity.
TCDD-activated AhR was independently reported to initiate a
rapid non-genomic signaling cascade, culminating in the activa-
tion of Src and Erk kinases (35–37). Recently, l-kyn–bound AhR
was found to promote IDO1 phosphorylation, through Src kinase-
mediated activity, which activates the signaling function of IDO1,
leading to the de novo synthesis of the enzyme via TGF-β pro-
duction (4, 13). Interestingly, in a model of murine vulvovaginal
candidiasis an increased expression of AhR was observed in the
vagina of both naïve and infected IDO1-deficient mice, suggesting
a further mechanism of mutual transcriptional regulation between
IDO1, the source of l-kyn, and its sensor AhR (38).
Besides its transcriptional activity, the non-genomic modality
of action of AhR could represent a further mechanism whereby
TRP metabolism and AhR cross their pathways. Analogous to
sex hormone receptors, regulated by AhR in both transcription-
ally and non-genomically fashions, IDO1 could represent another
substrate for the ubiquitin ligase activity of CUL4BAhR.
Proteasome-mediated degradation of IDO1 has been described
in DCs under IL-6-driven pro-inflammatory condition (3). The
ubiquitination of the enzyme is mediated by SOCS3 protein that
signals the enzyme to the proteasome. The mechanism is particu-
larly active in inflammatory DCs, where SOCS3 is highly expressed
and the cells are not required to manifest an immunoregulatory
phenotype. Regulatory proteolysis of IDO1 via the ubiquitin–
proteasome system may represent a non-genomic means of
switching off the enzyme. Similar to SOCS3, the CUL4BAhR com-
plex could promote the ubiquitination of IDO1, targeting it for
proteasomal degradation. Physiologically, the non-genomic mod-
ulation of IDO1 by ligand-bound AhR could be taken as a typical
negative feedback loop of enzyme regulation, where the same
trigger (liganded AhR) of its transcriptional expression can also
act as a quencher of the protein function, by promoting pro-
teasomal degradation. Such a mechanism would contribute to
a fine modulation of IDO1-based immunoregulatory response.
The hypothetical view of AhR-driven proteasomal degradation of
IDO1 is based on several observations that include the finding
that the enzyme is a proteasome substrate (3). Interestingly, both
IL-6 and SOCS3 (the trigger of the ubiquitination of IDO1) were
independently reported to be induced by activated AhR (33, 39).
In addition, SOCS2 – a member of the SOCS family in which
SOCS3 likewise belongs – is induced by l-kyn–activated AhR, and
it promotes the ubiquitination of the adapter protein TRAF6 (29).
Overall, these findings suggest that activated AhR, through its tran-
scriptional activity, is capable of inducing all of the components
(i.e., IL-6, SOCS3, and IDO1) of a putative feedback loop, promot-
ing intracellular conditions ensuring IDO1 ubiquitination and
proteasomal degradation. In addition, post-translational modi-
fications of substrates, such as phosphorylation, typically serve
for recruiting E3 ubiquitin ligases. In fact, tyrosine phosphory-
lation of the two ITIM motifs in the small domain of IDO1 is
needed for anchoring SOCS3 protein that bridges E3 ubiquitin
ligase (3). Interestingly, IDO1 phosphorylation may be promoted
by AhR activity in conventional DCs in a model of endotoxin
tolerance (13).
In this hypothetical scenario, AhR would play the canonical
role of transcription factor, capable of inducing the stimuli (IL-
6 and SOCS3) responsible for ubiquitination of IDO1 enzyme,
and would promote – through a non-canonical pathway – the
phosphorylation of IDO1 required for anchoring SOCS3. It is
also likely that the ubiquitin ligase activity ascribed to AhR might
directly act on IDO1 as a substrate, bypassing the “bridging” func-
tion mediated by SOCS3 (Figure 1). If so, the direct molecular
association of CUL4BAhR with IDO1 enzyme should be charac-
terized. All of the previously described complexes of CUL4BAhR
with both ER/AR and β-catenin are localized into the nucleus, as
involving the association of ligand-bound AhR with the specific
nuclear translocator Arnt. A major question relates to the subcel-
lular location where CUL4BAhR would bind the substrate IDO1.
There is no evidence of a nuclear localization of IDO1 enzyme or
of a cytosolic localization of CUL4BAhR. Thus, one should postu-
late that AhR assembles an ubiquitin ligase complex that involves
different molecular partners, not necessarily requiring the nuclear
translocation. In this regard, the C-terminus of Hsp70-interacting
protein (CHIP), a quality-controlling ubiquitin ligase, reportedly
promotes degradation of AhR. Since both CHIP and unliganded
AhR are mainly located in the cytosol, the degradation of AhR
through CHIP is likely to occur in the cytosol (40).
A second question relates to the nature of the AhR ligand that
could target IDO1 as a substrate for ubiquitination. In view of
a fine cross-talk between the TRP metabolism and AhR activity,
l-kyn and the downstream TRP metabolites could be good can-
didates for playing this role in a negative feedback loop, aimed at
controlling IDO1 enzymatic activity. As it holds true of ER/AR
signaling, in which AhR appears to modulate the receptors both
positively and negatively, although l-kyn has been shown to tran-
scriptionally induce IDO1 expression via AhR, later in an inflam-
matory context, the same molecules generated by IDO1 enzymatic
activity could also promote IDO1 ubiquitination and proteasomal
degradation.
Thus, l-kyn and its derivatives along the kynurenine pathway,
exploiting the genomic and non-genomic modality of action of
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FIGURE 1 | Aryl hydrocarbon receptor-mediated regulatory proteolysis
of IDO1. Ligand-operating aryl hydrocarbon receptor (AhR) promotes both
genomic and non-genomic activity. After nuclear translocation,
ligand-bound AhR dimerizes with the AhR nuclear translocator (Arnt) and
activates the transcription of target genes through AhR-responsive
elements (AHREs). Both IL-6 and SOCS3 are AhR-responsive genes and
may be independently induced by the genomic activity of AhR. In the
cytosol SOCS3, by anchoring tyrosine phosphorylated IDO1, brings the
enzyme close to the E3 ubiquitin complex (E3) that promotes the
polyubiquitination and the proteasomal degradation of IDO1. The
non-genomic activity of ligand-bound AhR promotes Src kinase-mediated
phosphorylation of IDO1, required for anchoring SOCS3. Ligand-bound AhR
can assemble an atypical E3 ubiquitin ligase complex, involving cullin 4B
(CUL4B), namely, CUL4BAhR. A direct association of CUL4BAhR with IDO1
protein has been prospected (inset) in determining the polyubiquitination
and the proteasomal degradation of IDO1.
the receptor AhR, could tightly control IDO1 activity in a sort of
negative feedback loop. By construing the ubiquitin ligase activity
of AhR as a sensor of environmental stress, as suggested in sex
hormone signaling (41), several inflammatory adverse effects of
dioxin-type ligands of AhR could be, at least in part, attributed
to the accelerated degradation of IDO1 that physiologically pre-
vents overreacting responses. In this regard, the appreciation of
exogenous/endogenous ligands that selectively activate the non-
genomic pathway of AhR might shed light on the biological role
of AhR-based modulation of IDO1.
The involvement of the atypical ubiquitin ligase activity of AhR
in the quenching of IDO1 activity may represent an attractive ther-
apeutic perspective. Translated into the clinic, the non-genomic
control of IDO1 by activated AhR becomes of great interest in neo-
plasia. The main strategy currently envisioned to tackle IDO1 clin-
ically is by inhibiting its enzymatic activity. The post-translational
modification of the enzyme,promoting its ubiquitination and pro-
teasomal degradation, could represent a valid alternative or a com-
plementary approach to the enzymatic inhibition. In this regard,
the purine analog, fludarabine, currently used as a chemother-
apeutic agent, has recently been proposed to act as a promoter
of proteasome-mediated degradation of IDO1 in tumors (42).
Noteworthy, the ubiquitin ligase function of AhR has also been
contextualized to the antiproliferative activity resulting from pro-
teasomal degradation of transcription factors (ER/AR, β-catenin)
that promote cell proliferation in target tissues. Although IDO1
does not possess a transcriptional activity of its own like other
substrates of CUL4BAhR, it is noteworthy that, in cancer tis-
sues, IDO1 plays a proliferative action (43–45), and therefore, the
putative CUL4BAhR-mediated degradation of IDO1 may result in
antiproliferative activity.
CONCLUSION
Dissecting the molecular mechanism of ubiquitin ligase activity of
AhR might lead to a better understanding of the diverse biological
effects induced by exogenous/endogenous AhR ligands. Specifi-
cally, clarifying this mechanism in relationship to the AhR–IDO1
axis might be of great interest in providing innovative IDO1-based
therapeutic targets. AhR-mediated non-genomic modulation of
IDO1 might provide druggable targets in cancer therapy, in alter-
native to or in combination with the already available enzyme
inhibitors. Thus, the identification of selective “non-toxic” AhR
ligands, activating the non-canonical pathway of the receptor,
represents an emerging area of research.
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